Angiotensin receptor blockers: RAAS blockade and renoprotection

References

• National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1–266
   Google Scholar
• Johnson CA, Levey AS, Coresh J, et al. Clinical practice guidelines for chronic kidney disease in adults: Part I. Definition, disease stages, evaluation, treatment, and risk factors. Am Fam Physician 2004;70:869–76
   PubMed Web of Science ®Google Scholar
• Bamgboye EL. Hemodialysis: management problems in developing countries, with Nigeria as a surrogate. Kidney Int 2003;83(Suppl):S93–5
   Google Scholar
• Alebiosu CO, Ayodele OE. The global burden of chronic kidney disease and the way forward. Ethn Dis 2005;15:418–23
   PubMed Web of Science ®Google Scholar
• Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154–69
   PubMed Web of Science ®Google Scholar
• Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005;16:489–95
   PubMed Web of Science ®Google Scholar
• Rossing P. Doubling of serum creatinine: is it sensitive and relevant? Nephrol Dial Transplant 1998;13:244–6
   PubMed Web of Science ®Google Scholar
• Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 1985;28:830–8
   PubMed Web of Science ®Google Scholar
• Stevens LA, Levey AS. Measurement of kidney function. Med Clin North Am 2005;89:457–73
   PubMed Web of Science ®Google Scholar
• Verelli, M. Chronic renal failure. Available at: www.emedicine. com/med/topic374.htm. [Last accessed 22 November 2007]
   Google Scholar
• Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296–305
   PubMed Web of Science ®Google Scholar
• Shulman NB, Ford CE, Hall WD, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 1989;13(5 Suppl):I80–93
   Google Scholar
• Ruilope LM, Salvetti A, Jamerson K, et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 2001;12:218–25
   PubMed Web of Science ®Google Scholar
• Desai M, Stockbridge N, Temple R. Blood pressure as an example of a biomarker that functions as a surrogate. AAPS J 2006;8:E146–52
   Google Scholar
• Ruilope LM, Zanchetti A, Julius S, et al. Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial. J Hypertens 2007;25:1473–9
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286:421–6
   PubMed Web of Science ®Google Scholar
• Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004;110:32–5
   PubMed Web of Science ®Google Scholar
• Rosario RF, Wesson DE. Primary hypertension and nephropathy. Curr Opin Nephrol Hypertens 2006;15:130–4
   PubMed Web of Science ®Google Scholar
• MacMahon S, Chalmers J. Blood pressure lowering and ACE inhibition for the avoidance of cardiac and cerebral events. Eur Heart J 2003;24:391–3
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206–52
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105–87
   Web of Science ®Google Scholar
• Brewster UC, Perazella MA. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med 2004;116:263–72
   PubMed Web of Science ®Google Scholar
• Snively CS, Gutierrez C. Chronic kidney disease: prevention and treatment of common complications. Am Fam Physician 2004;70:1921–8
   PubMed Web of Science ®Google Scholar
• Perneger TV, Whelton PK, Klag MJ. History of hypertension in patients treated for end-stage renal disease. J Hypertens 1997;15:451–6
   PubMedGoogle Scholar
• Perera GA. Hypertensive vascular disease; description and natural history. J Chronic Dis 1955;1:33–42
   PubMedGoogle Scholar
• Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 2001;104:1985–91
   PubMed Web of Science ®Google Scholar
• Ravera M, Re M, Deferrari L, Vettoretti S, Deferrari G. Importance of blood pressure control in chronic kidney disease. J Am Soc Nephrol 2006;17:S98–103
   Google Scholar
• Taal MW. Slowing the progression of adult chronic kidney disease: therapeutic advances. Drugs 2004;64:2273–89
   PubMed Web of Science ®Google Scholar
• Jafary MH. Renoprotective benefits of renin-angiotensin system inhibition. What’s the evidence? Pak J Med Sci 2002;18:311–5
   Google Scholar
• Long DA, Price KL, Herrera-Acosta J, Johnson RJ. How does angiotensin II cause renal injury? Hypertension 2004;43:722–3
   Google Scholar
• Epstein BJ. Elevations in serum creatinine concentration: concerning or reassuring? Pharmacotherapy 2004;24:697–702
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Delles C, Mimran A, et al. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care 2007;30:1351–16
   PubMed Web of Science ®Google Scholar
• Johnson DW, Usherwood T. Chronic kidney disease – management update. Aust Fam Physician 2005;34:915–23
   PubMedGoogle Scholar
• Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003;41:565–70
   PubMed Web of Science ®Google Scholar
• Ruilope LM. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers? Acta Diabetol 2005;42(Suppl 1):S33–41
   PubMedGoogle Scholar
• Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–9
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851–60
   PubMed Web of Science ®Google Scholar
• Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345: 870–8
   Google Scholar
• Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106:672–8
   PubMed Web of Science ®Google Scholar
• Haller H, Viberti GC, Mimran A, et al. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J Hypertens 2006;24:403–8
   PubMed Web of Science ®Google Scholar
• Hollenberg NK, Parving H-H, Viberti G, et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 2007;25: 1921–6
   Google Scholar
• Rossing K, Schjoedt KJ, Jensen BR, et al. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 2005;68:1190–8
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941–51
   PubMed Web of Science ®Google Scholar
• Barnett A. Preventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial. J Am Soc Nephrol 2006;17(4 Suppl 2):S132–5
   Google Scholar
• Strojek K, Grzeszczak W, Gorska J, et al. Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy? J Am Soc Nephrol 2001;12:602–5
   PubMed Web of Science ®Google Scholar
• Adler AI, Stevens RJ, Manley SE, et al; UKPDS Group. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63: 225–32
   Google Scholar
• Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001;135:73–87
   PubMed Web of Science ®Google Scholar
• Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001;285:2719–28
   PubMed Web of Science ®Google Scholar
• Feringa HH, Karagiannis SE, Chonchol M, et al. Lower progression rate of end-stage renal disease in patients with peripheral arterial disease using statins or angiotensin-converting enzyme inhibitors. J Am Soc Nephrol 2007;18:1872–9
   PubMed Web of Science ®Google Scholar
• Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-convertingenzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361:117–24
   PubMed Web of Science ®Google Scholar
• Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005;366:2026–33
   PubMed Web of Science ®Google Scholar
• Garcia-Donaire JA, Segura J, Ruilope LM. Clinical trials in nephrology: success or failure. Curr Opin Nephrol Hypertens 2007;16:59–63
   PubMed Web of Science ®Google Scholar
• Adler A, Stratton I, Shine B. Renoprotective effects of renin-angiotensin-system inhibitors. Lancet 2006;367:897–8
   Google Scholar
• de Zeeuw D, Lewis EJ, Remuzzi G, et al. Renoprotective effects of renin-angiotensin-system inhibitors. Lancet 2006;367:899–900
   PubMed Web of Science ®Google Scholar
• Mann JF, Ritz E, Kunz R. Renoprotective effects of renin-angiotensin-system inhibitors. Lancet 2006;367:900–2
   Google Scholar
• Parving HH, Rossing P. Renoprotective effects of renin-angiotensin-system inhibitors. Lancet 2006;367:898–9
   PubMed Web of Science ®Google Scholar
• Wogen J, Kreilick CA, Livornese RC, et al. Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usual-care setting. J Manag Care Pharm 2003;9:424–9
   PubMedGoogle Scholar
• Agarwal R. Add-on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int 2001;59:2282–9
   PubMed Web of Science ®Google Scholar
• Teo K, Yusuf S, Sleight P, et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004;148:52–61
   PubMed Web of Science ®Google Scholar
• Codreanu I, Perico N, Remuzzi G. Dual blockade of the renin-angiotensin system: the ultimate treatment for renal protection? J Am Soc Nephrol 2005;16(Suppl 1):S34–8
   Google Scholar
• Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000;160:685–93
   PubMed Web of Science ®Google Scholar